Triatholon Medical Ventures discusses Role of Venture Capital in Regenerative Medicine

Even though the venture capital model has faced trouble in the economic downturn, George Emont of Triathalon Medical Ventures says regenerative medicine investments are NOT a lost cause. Funds have shrunk, companies have closed, and the number of exits decreased, yet the number of investments in early stage biotech companies have only gone up over the past ten years.

Regenerative medicine technologies are more complex than traditional small molecule drugs, but this complexity can be tolerated by investors if the therapy is effective. George says that telling your story to a venture capitalist BEFORE you need money is a great way to excite the investor. These pre-money meetings are less tense than traditional pitch meetings, and they allow you to get feedback on the technology and financing strategy. Developing this relationship early gives an investor time to get to know your company and understand the complexity of your regenerative medicine technology, increasing your chance of obtaining funding.

-Original content provided by an on-site blogger at the Stem Cells USA & Regenerative Medicine Congress